Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration

James Robert Brašić1,*, Zoltan Mari2, Alicja Lerner3, Vanessa Raymont1, Eram Zaidi1, and Dean F. Wong1

1Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Section of High Resolution Brain Positron Emission Tomography Imaging, Johns Hopkins Outpatient Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2Department of Neurology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, 1800 Orleans Street, Baltimore, Maryland, USA 3Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, USA

Abstract

Heat has been reported to exert variable effects on people with Gilles de la Tourette syndrome (TS). At age 24 years, a 32-year-old right-handed man with TS experienced a marked reduction in tics for two years after undergoing dehydration by entering a hot tub at 103°F (39.4°C) to 104°F (40.0°C) for 3 to 4 hours. On the Yale Global Tic Severity Scale (YGTSS) he scored 55 seven months before dehydration and 13 one month after dehydration. An intense heat exposure and dehydration led to an apparent remission in tics. The remission continued without the use of prescribed or nonprescribed medications or substances for two years until tics returned in the worst ever exacerbation after a tetanus immunization. The heat exposure may have altered at least temporarily his thermostat for normal heat-loss mechanisms through dopaminergic pathways from the anterior hypothalamus to the basal ganglia and the substantia nigra. Whether or not that mechanism or some other mechanism relevant to the heat exposure and/or dehydration is at play, the sudden and marked improvement in his tics needs further attention. Prospective testing of the heat and dehydration effect on tics should be pursued.

Keywords

Basal ganglia; Dopamine; Hypothalamus; Substantia nigra; Thermoregulation; Thermostat; Tics

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: James Robert Brašić, Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Section of High Resolution Brain Positron Emission Tomography Imaging, Johns Hopkins Outpatient Center, Johns Hopkins University School of Medicine, 601 North Caroline Street, Room 3245, Baltimore, Maryland, USA, Tel: +001-410-955-8354; brasic@jhmi.edu.

Conflict of Interest

The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
Introduction

Anecdotal reports of Gilles de la Tourette syndrome (TS) have suggested either improvement or worsening with heat [1]. Gilles de la Tourette himself reported that acute fever alleviated tics [1,2]. On the other hand, five of ten adult men with TS demonstrated prominent worsening of tics when the ambient temperature was increased from 22°C (71.6°F) to 35°C (95.0°F) [3]. Similarly, some people with autism, another developmental disability, demonstrate improvement of stereotypies and other movements with high temperature [4]. Reports on heat’s effect on tics and stereotypies vary between improvement [1,2] and worsening [3] without reaching a clear consensus.

People with TS typically experience a decrement in tics with dopamine-receptor blocking drugs and an increment in tics from stimulants [1,3]. Release of dopamine in the preoptic area and the anterior hypothalamus plays a role in thermoregulation [3]. Although circuits for heat regulation may not overlap the circuits generating tics in TS, there may be indirect relationships between these circuits. Thus, the release of dopamine may play a role in mediating the effects of heat on tic intensity in people with TS [3].

There have been mixed reports on the rate of spontaneous remission in TS, as defined by greater than 10-point improvement the total score for tics (0-50) including both motor tics (0-25) and phonic tics (0-25) on the Yale Global Tic Severity Scale (YGTSS) [5]. Some investigators found a remission rate as low as 2/31 [6], while others reported somewhat higher rates [7-11]. When observed, spontaneous remission tends to occur at ages younger than the twenties, in patients who had shorter duration of illness, and with overall lower severity scores [12]. Based on the available literature on spontaneous remission, our patient, with moderately severe, long-standing TS in his mid-twenties, represents an exceedingly low probability for spontaneous remission.

Case Report

A young man participated in multiple assessments during research studies approved by the Institutional Review Board of the Johns Hopkins University School of Medicine, Baltimore, Maryland. He reported that he had induced dehydration several days after the episode without the consent or approval of the study physicians.

Clinical history

Since the age of 7 years, he experienced motor tics, including eye blinking, grimacing, and movements of head, shoulders, and fingers, and phonic tics, including grunting, snorting, and sniffing. Tics were exacerbated by cold, fatigue, and anxiety. Tics waxed and waned. Since childhood he experienced multiple tics simultaneously such as turning head to his shoulder along with a shoulder shrug.

Since the age of 10 years, he experienced recurrent episodes of 2 to 3 months of daily emesis occurring intermittently throughout the year alternating with complete resolution of the emesis for 2 to 3 months. Each episode of emesis was preceded by an uncontrollable sensation in his throat, a short premonitory awareness of a feeling that the food is going to
regurgitate. The emesis occurred only when eating solid foods. Emesis fluid never contained bile or stomach contents. He experienced a sore throat when he had emesis. Emesis occurred after one or two bites of food or midway through each meal. He successfully resumed eating after completing the emesis. Antacids did not relieve the emesis. He undertook diets with foods of various textures without beneficial effects. The symptoms occurred only during eating. He had no other swallowing difficulty, no nausea, no abdominal pain, and no odynophagia.

He was unable to carry parcels with bottles for fear that they could be damaged if he experienced tics.

At age 22, trials of clonidine and topiramate produced minimal effect on tics.

At age 23, he began to occasionally smoke marijuana with relief of tics for 3 to 4 days.

At age 23 years, 5 months, he had his baseline evaluation. For the baseline evaluation please refer to Table 1 for objective assessments.

**Family history**

His mother has TS. His sister has obsessive-compulsive disorder. He is married with one child. At age 3 and a half years, his 5-year-old son began to display motor tics, including eye blinks and simultaneous head movements to the shoulder along with shoulder shrugs, and a phonic tic, exaggerated coughing, similar to the proband.

**Other histories**

His past medical, surgical, social, developmental, and family histories and his review of symptoms were otherwise noncontributory.

**Clinical course**

At the age of 24 years and one month, he deliberately induced dehydration by entering a hot tub of 103°F for 3 and a half hour. During the last one and a half hour in the tub, he noticed that his tics had subsided. He reported that his tics had not recurred. After leaving the hot tub, he vomited clear fluid. He drank water because he was thirsty. He then regurgitated the fluid. After leaving the tub he experienced cramps in his legs, arms, and neck. For two days after leaving the hot tub, his urine was pinkish orange. He felt weak for a couple of days after leaving the hot tub. A month after the dehydration, he scored 13 for motor tics, 0 for phonic tics, and 0 for impairment on the YGTSS [5].

Please refer to Table 1 for a record of the multiple assessments to document his improvement. He was able to work full time as a computer technician. He remained almost completely free of tics for 2 years after heat-induced dehydration. During this remission he denied the use of medications and substances without a prescription. Please refer to supplementary materials for video segments before and after his dehydration.
At the age of 27, he experienced the worst ever acute exacerbation of all tics for two weeks after a tetanus immunization. The tics gradually returned to a mild level. He did not use medications or cannabis.

At the age of 29, he began using Δ⁹-tetrahydrocannabinol (THC) as an inhaled vapor nightly. His tics remain at a mild level. He has emesis approximately every six months. He has no exacerbation of tics with cold. He works ten hour a day for two jobs. He readily carries stock including eggs to shelves for a job without problems.

**Discussion**

At age 25, a young man with TS experienced an almost full remission of symptoms sustained for 18 months after undergoing a presumptive dehydration in a hot tub at 103°F (39.4°C) to 104°F (40°C) for 3 to 4 hours.

Cerebral hyperthermia results in an increased blood flow to the brain [33]. Heat exhaustion is a moderate illness resulting from depletion of water and salt associated with core body temperatures between 37°C and 40°C [34]. Heat produced alterations in both excitatory neurotransmitters, aspartate and glutamate, and inhibitory neurotransmitters, gamma-aminobutyric acid (GABA) and glycine [35]. Since dysfunction of the GABA-ergic system is a major effect of heat on the nervous system, the reduced inhibition resulting from damage to GABA neurotransmission may result in increased excitatory neurotransmission in response to heat [35].

Increased excitatory neurotransmission may stimulate further dopaminergic neurotransmission and may predispose a person to develop seizures [35]. Sustained excitatory neurotransmission may have produced a marked phasic increase in dopamine in our patient to result in a lasting effect on thermoregulation by the dopaminergic pathways from the anterior hypothalamus to the basal ganglia and the substantia nigra. Heat and/or dehydration may have led to tiny infarcts in our patient’s dopaminergic pathways from the anterior hypothalamus to the basal ganglia and the substantia nigra. The hyperthermia experienced by this man may have reset his thermostat for normal heat-loss mechanisms through dopaminergic pathways from the anterior hypothalamus to the basal ganglia and the substantia nigra. Whether or not that mechanism or some other mechanism relevant to the heat exposure and/or dehydration is at play, the sudden and marked improvement in his tics needs further attention. Prospective testing of the heat and dehydration effect on tics should be pursued. Clinical trials of dehydration and heat on TS may prove beneficial. The patient has been informed that unsupervised self-induced dehydration may result in serious morbidity and mortality; he has not repeated dehydration.

The patient has noted beneficial effects of tetrahydrocannabinol (THC). He daily utilizes an inhaled vapor of THC nightly. THC, an antagonist of the cannabinoid receptor, has been utilized as a treatment for a spectrum of neuropsychiatric disorders [36]. While acute administration of THC produces increased dopamine release, chronic use reduces dopaminergic neurotransmission [37]. The interactions of THC with the dopaminergic system are complex, and not completely elucidated, however few modes of interactions...
described result in decreased activity of the dopaminergic system such as: 1) in humans chronic cannabis intake reduces dopamine synthesis capacity in the striatum as seen in a positron emission tomography (PET) study with 18-F-DOPA [38], 2) dopamine release is blunted in chronic human cannabis users [39], and 3) dopamine transporter (DAT) density is reduced in chronic cannabis users as seen in the PET study with 11-C PE2I, a selective DAT radioligand [40].

Because it was postulated that hypersensitivity of dopamine receptors and/or hyperactivity of dopaminergic neurons underlay the pathophysiology of Tourette syndrome [41,42], decrease of dopaminergic tone due to THC effects might have beneficial effects on tics severity. A randomized, double-blind, placebo-controlled crossover single-dose trial of THC in 12 patients with TS demonstrated significant improvements of tics and obsessive-compulsive behaviors [43]. A randomized, double-blind, placebo-controlled clinical trial of THC in 24 patients with TS demonstrated a significant reduction in tics with THC [44]. Nevertheless, systematic reviews concluded that the evidence is insufficient to support the use of THC and other cannabinoids to treat tics and obsessive-compulsive behaviors in people with TS [45,46]. Clinical trials with of THC for TS incorporating monitoring of dopaminergic and cannabinoid neurotransmission are needed to determine if THC is effective for TS.

This case also illustrates retching and vomiting, rare manifestations of tics in TS [47,48].

Limitations

A placebo effect cannot be excluded in this open label exposure. Although the patient repeatedly exhibited normal temperatures during his baseline evaluation six months before his remission, we lack measured temperatures after the exposure to the hot bath. Given the relatively common occurrence of spontaneous remission, one could make an argument that association between two relatively common occurrences, heat exposure and remission of TS may be somewhat difficult to establish, given the high likelihood of co-occurrence by simple chance. Although he denied recent use of marijuana at each assessment, he may have experienced an effect of prior use of cannabis and related agents containing tetrahydrocannabinol [49]. Nevertheless, the occurrence of heat exposure and remission of TS may be chance. Spontaneous remissions of TS typically occur in adolescence. This patient is older than the typical adolescent to undergo a remission of TS. This single case report does not establish a causal sequence between heat-induced dehydration and remission of TS.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was sponsored by the Tourette Association of America, Brain and Behavior Research Foundation (NARSAD), the Essel Foundation, a BriteStar Bridge Award of The Johns Hopkins University, the Intellectual & Developmental Disabilities Research Center (U54 HD079123) of the Kennedy Krieger Institute, Baltimore, Maryland, the National Institutes of Health (NIH) by Public Health Service Grant DA09482, and the National
Center for Research Resources of the NIH M01RR00052 (Clinical Research Unit). Earlier versions of this study were presented at the 15th International Congress on Parkinson’s Disease and Movement Disorders, Toronto, Canada, June 5-9, 2011 [50], and the 1st World Congress on Tourette Syndrome and Tic Disorders, London, UK, June 24-26, 2015 [51]. We received no funds for covering the costs to publish in open access.

Grants

This research was sponsored by the Tourette Association of America, the Brain and Behavior Research Foundation (NARSAD), the Essel Foundation, the National Institutes of Health (NIH) by Public Health Service Grant DA09482, a BriteStar Bridge Award of The Johns Hopkins University, the Intellectual & Developmental Disabilities Research Center (U54 HD079123) at the Kennedy Krieger Institute of Johns Hopkins Medical Institutions in Baltimore, Maryland, and the National Center for Research Resources of the NIH M01RR00052 (Clinical Research Unit).

References

1. Lombroso PJ, Mack G, Scahill L, King RA, Leckman JF (1991) Exacerbation of Gilles de la Tourette’s syndrome associated with thermal stress: a family study. Neurology 41: 1984–1987.1745360

2. Lajonchere C, Nortz M, Finger S (1996) Gilles de la Tourette and the discovery of Tourette syndrome: includes a translation of his 1884 article. Arch Neurol 53: 567–574.8660160

3. Scahill L, Lombroso PJ, Mack G, Van Wattum PJ, Zhang H, et al. (2001) Thermal sensitivity in Tourette syndrome: preliminary report. Percept Mot Skills 92: 419–432.11361302

4. http://emedicine.medscape.com/article/912781-overview.

5. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, et al. (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28: 566–573.25627815

6. Ohta M, Kano Y (2003) Clinical characteristics of adult patients with tics and/or Tourette’s syndrome. Brain Dev (Suppl 1) 25: S32–S36.14980370

7. Coffey BJ, Biederman J, Geller DA, Spencer T, Park KS, et al. (2000) The course of Tourette’s disorder: a literature review. Harv Rev Psychiatry 8: 192–198.11038344

8. Coffey BJ, Biederman J, Geller D, Frazier J, Spencer T, et al. (2004) Reexamining tic persistence and tic-associated impairment in Tourette’s disorder: findings from a naturalistic follow-up study. J Nerv Ment Dis 192: 776–780.15505522

9. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, et al. (1998) Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 102: 14–19.9651407

10. Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123: 425–462.10686169

11. Rubenstein LA, Shprecher DR, Frank SA, Kurlan RM (2009) Age at tic remission in patients with Tourette syndrome. Mov Disord 24 (Suppl 1): S501.

12. García-Ribes A, Martí-Carrera I, Martínez-González MJ, Garaizar C, Prats-Viñas JM (2003) Factors that influence the short-term remission of tics in children with the syndrome of Gilles de la Tourette. Rev Neurol 37: 901–903.14634915

13. http://emedicine.medscape.com/article/1151826-overview.

14. Brašić JR (2003) Treatment of movement disorders in autism spectrum disorders. In Autism Spectrum Disorders. Hollander E, Ed; Marcel Dekker, Inc.: New York, USA, 24:273–346.

15. http://www.eqaimh.org/pdf/tool_aims.pdf

16. http://www.scirp.org/(S(351jmbntvnsjt1aadkposzje))/reference/ReferencesPapers.aspx?ReferenceID=1265746

17. Leckman JF, Towbin KE, Ort SI, Cohen DJ (1988) Clinical assessment of tic disorder severity In Tourette’s syndrome and tic disorders. Wiley: New York, USA, 55–78.

18. Pato MT, Pato CN (1991) Psychometrics in obsessive-compulsive disorder. In The psychobiology of obsessive-compulsive disorder Zohar J, Insel T, Rasmussen S, Eds, Springer, New York, USA, 44–88.
19. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, et al. (1989) The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 25: 222–226.2574895

20. Brašić JR, Zhou Y, Musachio JL, Hilton J, Fan H, et al. (2009) Single photon emission computed tomography experience with (S)-5-[123]Iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. Synapse 63: 339–358.19140167

21. McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, et al. (2002) Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology 26: 537–545.11927178

22. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 799–812.

23. Woerner MG, Mannuzza S, Kane JM (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 24: 112–117.3387514

24. Brašić JR (2000) Differentiating myoclonus from tics. Psychol Rep 86:155–156.10778264

25. Sachdev P (1994) A rating scale for acute drug-induced akathisia: development, reliability, and validity. Biol Psychiatry 35: 263–271.7910487

26. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672–676.2574607

27. Simpson GM, Lee JH, Zoubok B, Gardos G (1979) A rating scale for tardive dyskinesia. Psychopharmacology 64: 171–179.115037

28. http://img.medscape.com/pi/emed/ckb/neurology/1134815-1149724-1151826-1558764.pdf

29. Robertson MM, Bannerjee S, Kurlan R, Cohen DJ, Leckman JF, et al. (1999) The Tourette Syndrome Diagnostic Confidence Index: development and clinical associations. Neurology 53: 2108–2112.10599790

30. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, et al. (1989) The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012–1016.2510699

31. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, et al. (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011.2684084

32. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, (4th edn), text revision (DSM-IV-TR™). American Psychiatric Association, Washington, DC, USA, 456–463.

33. Kiyatkin EA (2004) Brain hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications. Curr Neurovasc Res 1: 77–90.16181068

34. Yeo TP (2004) Heat stroke: a comprehensive review. AACN Clin Issues 25: 280–293.

35. Wetsel WC (2011) Hyperthermic effects on behavior. Int J Hyperthermia 27: 353–373.2159189

36. Quezada J, Coffman KA (2018) Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs 32: 33–45.29335879

37. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD (2016) The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature 539:369–377.27853201

38. Bloomfield MAP, Morgan CJ, Egerton A, Kapur S, Curran HV, et al. (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75: 470–478.23820822

39. Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, et al. (2014) Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA 111: E3149–E3156.25024177

40. Leroy C, Karila L, Martino J-L, Lukasiewicz M, Duchesnay E, et al. (2012) Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict Biol 17: 981–990.21812871

41. Butler IJ, Koslow SH, Seifert WE, Caprioli RM, Singer HS (1979) Biogenic amine metabolism in Tourette syndrome. Ann Neurol 6: 37–39.292354

42. Singer HS, Butler IJ, Tune LE, Seifert WE, Coyle JT (1982) Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 12: 361–366.6184010
43. Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, et al. (2002) Treatment of Tourette's syndrome with Δ⁹-tetrahydrocannabinol: Pharmacopsychiatry 35: 57–61.11951146

44. Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, et al. (2003) Δ⁹-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry 64: 459–465.12716250

45. Curtis A, Clarke CE, Rickards HE. (2009) Cannabinoids for Tourette’s syndrome. Cochrane Database Syst Rev 4:CD006565.

46. Martino D, Pringsheim TM (2018) Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother 18: 125–137.29219631

47. Rickards H, Robertson MM (1997) Vomiting and retching in Gilles de la Tourette syndrome: a report of ten cases and a review of the literature. Mov Disord 12: 531–535.9251071

48. Robertson MM, Stern JS. (1998) Tic disorders: new developments in Tourette syndrome and related disorders. Curr Opin Neurol 11: 373–380.9725084

49. Kanann AS, Jakubovski E, Müller-Vahl K (2017) Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci 7:47.

50. Brasic JR, Mari Z, Raymont V, Condouris S, Wong DF (2011). Partial remission of Gilles de la Tourette syndrome in a 24-year-old man after heat-induced dehydration. Mov Disord 26:S368.

51. Brasic J, Mari Z, Lerner A, Raymont V, Zaidi E, et al. (2015) Almost full remission of Tourette syndrome in a 25-year-old man after heat-induced dehydration. In 1st World Congress on Tourette Syndrome & Tic Disorders, London, UK pp:38–44.
**Table 1:**
Objective assessments of a 25-year-old man 7 months before and 1 and 11 months after an almost full remission following dehydration in a hot tub at 103°F (39.4°C) to 104°F (40.0°C) for 3 to 4 hours.

| Instrument                                                                 | Range of scores                  | Six months before remission | One month after remission | Eleven months after remission |
|---------------------------------------------------------------------------|----------------------------------|----------------------------|---------------------------|------------------------------|
| Urine drug toxicology for tetrahydrocannabinol                            | Negative or positive             | Negative                   | Positive                   | Positive                     |
| Abnormal Involuntary Movement Scale (AIMS) [13-15]                        | (0.40)                           | 9                         | 0                         | 1                            |
| Clinical Global Impression (CGI) Severity Index (SI) [16]                  | (0.7)                            | 4 Moderately mentally ill  | 3 Mildly ill               | 2 Borderline mentally ill    |
| Clinical Global Impression (CGI) Global Improvement (GI) [16]              | (0.7)                            | 4 No change                | 2 Much improved            | 1 Very much improved         |
| Clinical Global Impression (CGI) Efficacy Index (EI) [16]                  | (0.16)                           | 13                        | 5                         | 13                           |
| Clinical Global Impression (CGI) Therapeutic effect [16]                  | Not applicable                   | Unchanged or worse         | Moderate                   | Unchanged or worse           |
| Clinical Global Impression (CGI) Side effects [16]                        | Not applicable                   | None                       | None                       | None                         |
| Clinical Global Impression (CGI) Attention Deficit Disorder (ADD) [17]     | (0.6)                            | 1 Borderline               | 0                         | 1 Borderline                 |
| Clinical Global Impression (CGI) Obsessive-Compulsive Disorder (OCD) [17]  | (0.6)                            | 3 Moderate                 | 2                         | 2 Mild                       |
| Clinical Global Impression (CGI) Tourette syndrome (TS) [17]              | (0.6)                            | 3 Moderate                 | 1                         | 1 Borderline                 |
| Clinical Global Improvement (CGI) Rater Global Evaluation (RGE) [18]       | (1.7)                            | 4 Unchanged                | 2 Much improved            | 1 Very much improved         |
| Hillside Akathisia Scale (HAS) Subjective items [13,19]                   | (0.8)                            | 0                         | 0                         | 0                            |
| Hillside Akathisia Scale (HAS) Objective items [13,19]                    | (0.12)                           | 6                         | 0                         | 0                            |
| Hillside Akathisia Scale (HAS) Clinical Global Impression (CGI) Severity of Akathisia (SA) [13,19] | (0.7) | 3 Mildly akathisic | 1 Normal, not akathisic | 1 Normal, not akathisic |
| Hillside Akathisia Scale (HAS) Clinical Global Impression (CGI) Global Improvement (GI) [13,19] | (0.7) | 4 No change | 1 Very much improved | 1 Very much improved |
| Magnetic resonance imaging of the brain [20, Table II, page 346]           | Normal or abnormal               | Normal                     | Normal                     | Normal                       |
| Maryland Psychiatric Research Center (MPRC) Brief Psychiatric Rating Scale (BPRS) Anchors [21-23] | (20,140) | 26 | 21 | 21 |
| Movement Disorders Checklist [14]                                         | (0.23)                           | 14                        | 8                         | 0                            |
| Myoclonus versus tic checklist [24]                                        | (~2.6)                           | 6                         | 3                         | 0                            |
| National Institutes of Mental Health (NIMH) Obsessive-Compulsive Scale (OCS) [18] | (0.15) | 5 | 2 | 1 |
| Rating Scale for Acute Drug-Induced Akathisia (RSADIA) Subjective [25]    | (0.9)                            | 0                         | 0                         | 0                            |
| Rating Scale for Acute Drug-Induced Akathisia (RSADIA) Objective [25]     | (0.21)                           | 1                         | 0                         | 0                            |
| Instrument                                                                 | Range of scores | Six months before remission | One month after remission | Eleven months after remission |
|---------------------------------------------------------------------------|-----------------|-----------------------------|---------------------------|------------------------------|
| Rating Scale for Acute Drug-Induced Akathisia (RSADIA) Global Rating [25] | (0,3)           | 0                           | 0                         | 0                            |
| Rating scale for drug-induced akathisia (RSDIA) Subjective [26]           | (0,6)           | 0                           | 0                         | 0                            |
| Rating scale for drug-induced akathisia (RSDIA) Objective [26]            | (0,3)           | 1                           | 0                         | 0                            |
| Rating scale for drug-induced akathisia (RSDIA) Global Clinical Assessment of Akathisia (GCAA) [26] | (0,5) | 1 | 0 | 0 |
| Rating Scale for Tardive Dyskinesia (RSTD) Face [27]                     | (16.96)         | 26                          | 17                        | 18                           |
| Rating Scale for Tardive Dyskinesia (RSTD) Neck and trunk [27]           | (8,48)          | 11                          | 8                         | 8                            |
| Rating Scale for Tardive Dyskinesia (RSTD) Extremities (upper) [27]       | (8,48)          | 11                          | 8                         | 8                            |
| Rating Scale for Tardive Dyskinesia (RSTD) Extremities (lower) [27]       | (8,48)          | 8                           | 8                         | 8                            |
| Rating Scale for Tardive Dyskinesia (RSTD) Entire body [27]              | (4,24)          | 4                           | 4                         | 4                            |
| Timed Stereotypies Rating Scale [14,28]                                   | (0,1000)        | 27                          | 2                         | 1                            |
| Tourette Syndrome Diagnostic Confidence Index (TSDCI) [29]                | (0,100)         | 61                          | Missing                   | 82                           |
| Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [30,31]                   | (0,40)          | 4                           | 10                        | 4                            |
| Obsessive-Compulsive Disorder through the application of the criteria current at the time of the study [32] to the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [30,31] | (0,1) | 0 | 1 | 0 |
| Yale Global Tic Severity Scale (YGTSS) Motor [5]                         | (0,25)          | 19                          | 13                        | 12                           |
| Yale Global Tic Severity Scale (YGTSS) Phonic [5]                        | (0,25)          | 9                           | 0                         | 11                           |
| Yale Global Tic Severity Scale (YGTSS) Impairment [5]                    | (0,50)          | 27                          | 0                         | 9                            |

*Obsessive-Compulsive Disorder (OCD) is diagnosed [32] if on the Y-BOCS [30,31] a person scores 2, 3, or 4 on any of the following items: 1 time spent on obsessions, or 2 interference from obsessions, or 3 distress of obsessions, or 6 time spent on compulsions, or 7 interference from compulsions, or 8 distress of compulsions*